This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Davidson, E. J. Articles by Stern, P. L. Search for Related Content PubMed PubMed Citation Articles by Davidson, E. J. Articles by Stern, P. L.

Association between Human Leukocyte Antigen Polymorphism and Human Papillomavirus 16-positive Vulval Intraepithelial Neoplasia in British Women¹

Immunology Group, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester M20 4BX [E. J. D., P. L. S.]; Academic Unit of Obstetrics and Gynaecology, St. Mary’s Hospital, Manchester M13 0JH [E. J. D., H. C. K.]; Transplantation Laboratory, Manchester Clinic Building, Manchester Royal Infirmary, Manchester M13 9WL [J. A. D.]; and Division of Virology, Department of Pathology, University of Cambridge, Addenbrooke’s Hospital, Cambridge CB2 2QQ [J. C. S., P .J. W. B.], United Kingdom

Polymorphisms in human leukocyte antigen (HLA) genes have been implicated in the risk for developing human papillomavirus (HPV)-associated cervical neoplasia. By comparison with local cadaver controls typed for HLA class I (n = 946) and II (n = 144) antigens, HPV-16-positive high grade vulval intraepithelial neoplasia patients (n = 42) showed significantly different frequencies of HLA-A2 [odds ratio (OR), 2.1; confidence interval (CI), 1.4–3.9], HLA-B7 (OR, 2.6; CI, 1.4–4.7), HLA-DRB1*01^01/02/04 (OR, 0.1; CI, 0.03–0.5), HLA-DRB1*11 (OR, 3.3; CI, 1.4–7.1), HLA-DRB1*13 (OR, 0), HLA-DQB1*05 (OR, 0.2; CI, 0.05–0.6), and HLA-DQB1*03032 (OR, 4.6; CI, 1.5–14.0). With the exception of HLA-B7 and HLA-DRB1*11, these significant differences were also seen comparative to local HPV-16-positive cervical carcinoma patients (n = 114), suggesting a specific immunogenetic contribution that is independent of HPV-16 infection in high-grade vulval intraepithelial neoplasia. Such factors are important to the development of HPV vaccines for treatment of cervical and vulval neoplasia.

This article has been cited by other articles:

				J. Hu, X. Peng, N. M. Cladel, M. D. Pickel, and N. D. Christensen Large cutaneous rabbit papillomas that persist during cyclosporin A treatment can regress spontaneously after cessation of immunosuppression J. Gen. Virol., January 1, 2005; 86(1): 55 - 63. [Abstract] [Full Text] [PDF]

				E. J. Davidson, C. M. Boswell, P. Sehr, M. Pawlita, A. E. Tomlinson, R. J. McVey, J. Dobson, J. St. C. Roberts, J. Hickling, H. C. Kitchener, et al. Immunological and Clinical Responses in Women with Vulval Intraepithelial Neoplasia Vaccinated with a Vaccinia Virus Encoding Human Papillomavirus 16/18 Oncoproteins Cancer Res., September 15, 2003; 63(18): 6032 - 6041. [Abstract] [Full Text] [PDF]